StateViewer

by Mayo Clinic  · Based in United States → — AI-powered insights for early and precise dementia diagnosis.
Neurology Nuclear Medicine Radiology

Contact for pricing

Overview

StateViewer is an artificial intelligence (AI) tool developed by Mayo Clinic’s Neurology Artificial Intelligence Program (NAIP) designed to assist clinicians in diagnosing various neurodegenerative diseases, particularly dementias.

What it does: StateViewer analyzes fluorodeoxyglucose positron emission tomography (FDG-PET) brain scans. It compares an individual patient’s scan to a large database of confirmed dementia cases to identify patterns of brain activity and glucose metabolism associated with specific types of dementia. The tool can identify patterns linked to nine types of dementia, including Alzheimer’s disease, Lewy body dementia, and frontotemporal dementia.

Who it is for: This tool is intended for neurologists and other clinicians involved in the diagnosis and management of patients with suspected neurodegenerative conditions. It may be particularly beneficial in care settings that may lack immediate access to specialized neurology expertise.

How it fits a clinical or practice workflow: StateViewer integrates into the diagnostic workflow by providing an AI-powered analysis of FDG-PET scans. The tool generates color-coded brain maps that visually highlight key areas of brain activity, offering a visual explanation of the AI’s findings to clinicians. This output can be reviewed during multidisciplinary case conferences to support diagnostic decision-making.

Notable capabilities: StateViewer has demonstrated the ability to identify dementia types with an 88% accuracy rate in studies. It has also been shown to potentially enhance the speed of scan interpretation and diagnostic accuracy for clinicians. The tool’s design aims to provide clear, interpretable insights to support clinicians in distinguishing between various complex neurodegenerative diseases.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Analyzes FDG-PET brain scans
  • Identifies patterns linked to 9 types of dementia (e.g., Alzheimer's, Lewy body, frontotemporal dementia, posterior cortical atrophy, corticobasal syndrome, progressive supranuclear palsy)
  • Compares patient scans to a large reference dataset of confirmed dementia cases (over 3,600 scans)
  • Produces color-coded brain activity maps highlighting disease patterns
  • Enhances diagnostic accuracy (88% accuracy in identifying dementia types)
  • Increases speed of interpretation (nearly twice as fast as standard workflows)
  • Improves diagnostic accuracy for clinicians (up to three times greater accuracy than standard practices)
  • Aids in distinguishing between dementias with similar symptoms
  • Provides visual explanations of AI findings for clinicians
  • Designed to support, not replace, clinical decision-making

Use Cases

  • Early and precise diagnosis of various dementia types
  • Supporting clinical decision-making in neurology
  • Expanding access to specialist-level insights in clinics lacking neurology expertise
  • Guiding treatment decisions for patients with dementia
  • Differentiating between multiple overlapping or coexisting dementia conditions
  • Assisting in the diagnosis of reversible causes of dementia

What Physicians Need to Know

Evidence Base
StateViewer was trained and validated on over 3,600 FDG-PET brain scans from individuals with confirmed dementia diagnoses and those with no cognitive decline. The underlying machine learning model uses a modified k-nearest neighbor (K-NN) algorithm.
Clinical Validation Studies
StateViewer has been successfully piloted by Mayo neurologists as a research tool. Studies have shown a significant enhancement in the accuracy of clinicians' interpretations of brain images, surpassing what is achievable with current tools alone. In a radiologic reader study, clinicians using StateViewer had 3.3 u00b1 1.1 times greater odds of making a correct diagnosis than those using standard-of-care practices. The tool achieved a sensitivity of 0.89 u00b1 0.03 and an area under the receiver operating characteristic (ROC) curve of 0.93 u00b1 0.02 in distinguishing neurodegenerative phenotypes. It correctly identified dementia types 88% of the time in a study.
Differential Diagnosis Support
StateViewer can identify 9 different types of dementia, including Alzheimer's disease, Lewy body dementia, frontotemporal dementia (including subtypes like behavioral variant, logopenic variant primary progressive aphasia, nonfluent primary progressive aphasia, semantic dementia), posterior cortical atrophy, corticobasal syndrome, and progressive supranuclear palsy. It is particularly helpful in distinguishing between dementia types with similar symptoms, such as Lewy body dementia and posterior cortical atrophy. The tool generates color-coded brain activity maps to highlight regions matching specific disease patterns.
Clinical Workflow Integration
StateViewer has been successfully piloted by Mayo neurologists as a research tool and is used for patients in Mayo's Alzheimer's Disease Treatment Clinic with a PET scan available. The outputs of StateViewer may be reviewed at weekly multidisciplinary case conferences to inform precision medicine-based recommendations. It has been shown to enable nearly twice the speed of interpretation. The platform is designed to integrate AI with clinician expertise to improve diagnostic accuracy and patient outcomes. It is deployed in practice on an investigational basis across the enterprise and the Mayo health system. StateViewer is a clinical decision support application that leverages AI and ML technology to improve diagnostic accuracy and efficiency, reducing reading time by 50%.
Physician Tip

StateViewer is a powerful AI tool designed to augment, not replace, clinical decision-making in diagnosing dementia. Leverage its ability to rapidly analyze FDG-PET scans and provide color-coded brain maps to enhance diagnostic accuracy and differentiate between complex neurodegenerative phenotypes, especially in cases with overlapping symptoms. The tool can significantly reduce interpretation time and offer expert-level insights, potentially expanding access to specialized dementia diagnostics.

StateViewer is a Mayo-created platform that takes an individual patient's PET scan and applies AI to find similar cases of brain disease in Mayo's distributed data network. It operates within the Mayo Clinic Cloud, an innovative technology platform developed in collaboration with Google Cloud, allowing real-time access and analysis of clinical imaging data. The platform, called NetD, connects cloud-based data, multimodal models, and clinical workflows to enable scalable and adaptive neurology. StateViewer is considered a Class 2 software as a medical device for analytics.

Details

Category Clinical Decision Support & Reference, Neurology AI, Radiology & Imaging AI
Pricing Contact for pricing
DeploymentCloud-computing approach (Mayo Clinic Cloud, in collaboration with Google Cloud)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Unknown AI-estimated

StateViewer is currently a research tool and has been successfully piloted by Mayo neurologists as a research tool. There is no information available about FDA clearance for StateViewer. While Mayo Clinic has had spin-offs receive FDA 510(k) clearance for other software-based decision support tools, this does not apply to StateViewer.

Integrations
EHR Not specified
Specialties Neurology, Nuclear Medicine, Radiology

What the Web Says

StateViewer is an AI tool developed by Mayo Clinic researchers to identify nine types of dementia, including Alzheimer's disease, from a single FDG-PET brain scan. It has shown high accuracy (88%) in identifying dementia types and can help clinicians interpret brain scans nearly twice as fast and with up to three times greater accuracy than standard methods. The tool provides color-coded brain maps to visually explain the AI's findings, making it accessible even to clinicians without specialized neurology training.

Overall: Positive

Strengths

  • High accuracy in identifying nine types of dementia (88%).
  • Significantly faster interpretation of brain scans (nearly twice as fast).
  • Up to three times greater diagnostic accuracy compared to standard workflows.
  • Aids in early and precise diagnosis, even with multiple co-occurring conditions.
  • Provides visual, color-coded brain maps for easier interpretation by all clinicians.
  • Potential to expand advanced diagnostic support to clinics lacking neurology expertise.

Limitations

  • Currently a research tool, with plans for expanded use and evaluation in various clinical settings.
  • The discovery cohort for training and testing may not fully represent broader clinical populations.
  • No information available from independent tech reviewers, Reddit, G2, or Capterra, indicating limited public or widespread commercial use/review outside of Mayo Clinic's research.

Based on reviews from: Mayo Clinic News Network, Neurology (medical journal), SciTechDaily, Patient Care Online, AI In Healthcare: AI Tool Helped Identify Forms Of Dementia With 88% Accuracy, How is artificial intelligence helping to diagnose dementia? - Mayo Clinic, Mayo Clinic Tests Neurology AI Program Using PET Scans to Detect Brain Diseases, 2025 Research Highlights: AI StateViewer | Mayo Clinic Connect

Last updated: 2026-10-02

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate StateViewer

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Mayo Clinic News Network
Mayo Clinic's AI tool identifies 9 dementia types, including Alzheimer's, with one scan
Mayo Clinic researchers have developed StateViewer, an AI tool that identifies nine types of dementia, including Alzheimer's, from a single FDG-PET brain scan, improving diagnostic accuracy and speed. The research was published in Neurology on June 27, 2025.
2025-06
Patient Care Online
Mayo Clinic AI Tool Allows Rapid, Precise Identification of 9 Types of Dementia From Single Brain Scan
StateViewer, an AI-based clinical decision support system from Mayo Clinic, can identify patterns of brain activity linked to nine dementia types from a single FDG-PET scan, achieving high sensitivity and ROC curve values in studies. The tool aims to expand access to specialist-level insights, particularly in areas with limited neurology expertise.
2025-07
SciTechDaily
New AI Tool Detects 9 Types of Dementia From a Single Scan
Mayo Clinic's StateViewer AI tool can detect nine types of dementia, including Alzheimer's, from a single brain scan, with 88% accuracy and significantly faster interpretation times. This advancement addresses challenges in early and precise dementia diagnosis.
2025-07
Mayo Clinic
How is artificial intelligence helping to diagnose dementia?
Mayo Clinic's StateViewer AI tool analyzes FDG-PET brain scans to identify patterns of sugar use, helping to diagnose different types of dementia with 88% accuracy. The tool compares scans to a database of over 3,600 previously diagnosed cases, aiding in faster and more accurate diagnoses.
2025-07
Mayo Clinic
Mayo Clinic Neurology AI Program tests platform to detect brain diseases
The Mayo Clinic Neurology Artificial Intelligence Program (NAIP) is testing StateViewer, an AI platform that uses PET scans to find similar cases of brain disease in Mayo's data network, aiming to enhance diagnostic accuracy for dementias like Alzheimer's. The platform has been successfully piloted as a research tool, doubling speed and tripling diagnostic accuracy for clinicians.
2024-12
Mayo Clinic Connect
2025 Research Highlights: AI StateViewer
In June 2025, Mayo Clinic Alzheimer's Disease Researchers introduced StateViewer, an AI tool that assists clinicians in interpreting FDG-PET scans to identify nine types of dementia. The tool is still in early use, with plans for expanded evaluation in clinical settings.
2025-12
Neurology
An FDG-PETu2013Based Machine Learning Framework to Support Neurologic Decision-Making in Alzheimer Disease and Related Disorders
This peer-reviewed article details the methodology behind StateViewer, an FDG-PET-based machine learning framework developed to support neurological decision-making in Alzheimer's disease and related disorders. The research was published in Neurology in June 2025.
2025-06
Mayo Clinic Platform
Deciphering the Puzzle of Dementia
Mayo Clinic Platform highlights how AI algorithms, including StateViewer, are making dementia diagnoses more precise. StateViewer improved diagnostic accuracy (AUC 0.92) when differentiating between posterior cortical atrophy and Lewy body dementia, with even better results when combined with standard approaches.
2025-12

Videos

Product demos, reviews, and walkthroughs for StateViewer.

View all on YouTube

Frequently Asked Questions

StateViewer is a clinical decision support (CDS) tool designed to provide real-time, evidence-based guidance at the point of care. It integrates with your existing EHR to offer patient-specific recommendations, alerts for potential drug interactions, and summaries of relevant clinical guidelines, aiming to enhance diagnostic accuracy and treatment efficacy.
StateViewer incorporates the latest clinical guidelines from recognized authorities and updates its knowledge base regularly. It provides clear citations for its recommendations, helping you demonstrate adherence to best practices and regulatory standards. The system also tracks user interactions for audit purposes, supporting compliance efforts.
Yes, there are several other CDS tools available, each with varying features. StateViewer differentiates itself through its intuitive interface, comprehensive integration capabilities, and a focus on actionable, patient-specific insights. While other tools may offer similar functionalities, StateViewer aims for a balance of robust evidence and user-friendly design to minimize alert fatigue and maximize utility.
StateViewer typically offers tiered pricing models based on the size of the practice or institution and the scope of features required. There are often subscription options for individual physicians, small clinics, and larger hospital systems, with varying levels of support and customization. Specific pricing details can be obtained by contacting our sales team for a personalized quote.
While StateViewer is a powerful tool, it's important to remember it's a support system, not a replacement for clinical judgment. Potential limitations include the need for accurate and complete EHR data for optimal recommendations, and the possibility of alert fatigue if not configured appropriately. It's designed to augment your decision-making, not automate it entirely, and its effectiveness relies on proper integration and user engagement.
StateViewer employs a dedicated team of medical experts and data scientists who continuously monitor new research, clinical trials, and guideline updates from authoritative sources. Its knowledge base is regularly updated and validated to ensure that the recommendations provided are based on the most current and evidence-based medical information available.
Yes, StateViewer offers a degree of customization to align with specific specialties and clinical pathways. While the core knowledge base is broad, physicians can often configure preferences, prioritize certain guidelines, and tailor alert settings to better suit their individual practice patterns and patient populations. This helps to optimize its relevance and minimize irrelevant notifications.

Related Tools

Cortex
Cortex
Clinical Decision Support & Reference
Cortex Workspace is a secure, HIPAA-compliant AI platform designed to streamline healthcare workflows and enhance decision-making for physicians.
SureMediks ProView
SureMediks (Rasimo Systems, LLC)
Clinical Decision Support & Reference
SureMediks is an AI-powered clinical decision support and metabolic health platform that automates care workflows for specialists, providing AI-generated patient summaries, automated chart review, and real-time biometric alerts.
SOAP Health
SOAP Health
Clinical Decision Support & Reference
SOAP Health is a Florida-based startup transforming patient intake with AI-powered diagnosis, offering a comprehensive solution that improves diagnosis accuracy and empowers patients and physicians.
Oxipit ChestLink
Oxipit (part of Sectra group)
Clinical Decision Support & Reference
Oxipit ChestLink is the world's first CE Class IIb-certified autonomous AI application for healthy chest X-ray reporting, capable of identifying normal studies with 99.9% sensitivity. It automates the reporting of normal chest X-rays, reducing radiologist workload and improving efficiency.
KATE AI
Mednition
Clinical Decision Support & Reference
KATE AI is a nurse-built clinical decision support tool for emergency departments that analyzes incoming patients in real-time to flag high-risk cases that standard acuity scoring might miss. It has supported over 5,000,000 patient visits, helping emergency teams deliver safer, faster, and more informed care.
MCG Health
MCG Health
Clinical Decision Support & Reference
MCG Health provides industry-leading evidence-based guidance and technologies to optimize health outcomes, drive operational efficiency, and achieve cost savings. Their solutions are utilized by thousands of hospitals, a majority of U.S. health plans, and various government health programs.

See all Clinical Decision Support & Reference tools →

Suggest an Edit → | Last Verified: 2026-07-01 | First Added: 2026-07-01
AI Tool Finder
AI-powered search. Results may not be comprehensive.